{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild+to+Moderate+Dementia&page=2",
    "query": {
      "condition": "Mild to Moderate Dementia",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild+to+Moderate+Dementia&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T22:28:53.536Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02560753",
      "title": "Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "T3D-959",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "T3D Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 36,
      "start_date": "2015-07",
      "completion_date": "2016-06-30",
      "has_results": true,
      "last_update_posted_date": "2018-07-30",
      "last_synced_at": "2026-07-23T22:28:53.536Z",
      "location_count": 3,
      "location_summary": "Delray Beach, Florida • Miami, Florida • Charlotte, North Carolina",
      "locations": [
        {
          "city": "Delray Beach",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02560753"
    },
    {
      "nct_id": "NCT02614131",
      "title": "A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Alzheimer's Disease",
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "LY2599666",
          "type": "DRUG"
        },
        {
          "name": "Solanezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo SC",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2015-12",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2020-06-17",
      "last_synced_at": "2026-07-23T22:28:53.536Z",
      "location_count": 3,
      "location_summary": "Glendale, California • Marlton, New Jersey • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Marlton",
          "state": "New Jersey"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02614131"
    },
    {
      "nct_id": "NCT00257673",
      "title": "Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "MEM 1003",
          "type": "DRUG"
        },
        {
          "name": "Placebo for MEM 1003",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memory Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 183,
      "start_date": "2005-11",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2008-05-06",
      "last_synced_at": "2026-07-23T22:28:53.536Z",
      "location_count": 57,
      "location_summary": "Northport, Alabama • Mesa, Arizona • Phoenix, Arizona + 51 more",
      "locations": [
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "El Centro",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00257673"
    },
    {
      "nct_id": "NCT01230853",
      "title": "A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Active Comparator: A",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator B",
          "type": "DRUG"
        },
        {
          "name": "Active Comparator B",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2010-08",
      "completion_date": "2013-02",
      "has_results": false,
      "last_update_posted_date": "2020-11-23",
      "last_synced_at": "2026-07-23T22:28:53.536Z",
      "location_count": 8,
      "location_summary": "Garden Grove, California • San Francisco, California • Orlando, Florida + 5 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01230853"
    },
    {
      "nct_id": "NCT05488951",
      "title": "The Influence of the Otago Exercise Program on Executive Function Among People Living With Mild to Moderate Dementia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dementia"
      ],
      "interventions": [
        {
          "name": "Otago Exercise Program",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Augusta University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2022-07-01",
      "completion_date": "2023-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-01-31",
      "last_synced_at": "2026-07-23T22:28:53.536Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05488951"
    },
    {
      "nct_id": "NCT00960531",
      "title": "A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "ACC-001+ QS21 (3mcg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACC-001 (10 mcg) + QS-21",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACC-001+QS-21 (30mcg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 160,
      "start_date": "2009-07",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2016-04-01",
      "last_synced_at": "2026-07-23T22:28:53.536Z",
      "location_count": 28,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00960531"
    },
    {
      "nct_id": "NCT00151502",
      "title": "To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 600,
      "start_date": "2002-11",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2021-02-18",
      "last_synced_at": "2026-07-23T22:28:53.536Z",
      "location_count": 40,
      "location_summary": "Sun City, Arizona • Fresno, California • Laguna Hills, California + 35 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00151502"
    },
    {
      "nct_id": "NCT00231946",
      "title": "ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "VP4896",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Voyager Pharmaceutical Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 555,
      "start_date": "2005-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-09-20",
      "last_synced_at": "2026-07-23T22:28:53.536Z",
      "location_count": 55,
      "location_summary": "Peoria, Arizona • Tucson, Arizona • Fresno, California + 49 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Lafayette",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00231946"
    },
    {
      "nct_id": "NCT04886063",
      "title": "Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "ATH-1017",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LeonaBio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 423,
      "start_date": "2021-06-30",
      "completion_date": "2024-10-23",
      "has_results": true,
      "last_update_posted_date": "2025-04-01",
      "last_synced_at": "2026-07-23T22:28:53.536Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04886063"
    },
    {
      "nct_id": "NCT01723826",
      "title": "A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Crenezumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 360,
      "start_date": "2012-12-07",
      "completion_date": "2017-02-08",
      "has_results": true,
      "last_update_posted_date": "2020-02-20",
      "last_synced_at": "2026-07-23T22:28:53.536Z",
      "location_count": 47,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 42 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01723826"
    }
  ]
}